Beijing Chunlizhengda Medical Instruments (HKG:1858) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥805.9m (down 33% from FY 2023).
- Net income: CN¥125.0m (down 55% from FY 2023).
- Profit margin: 16% (down from 23% in FY 2023). The decrease in margin was driven by lower revenue.
- EPS: CN¥0.33 (down from CN¥0.72 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Beijing Chunlizhengda Medical Instruments Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 28%. Earnings per share (EPS) also missed analyst estimates by 53%.
Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong.
Performance of the Hong Kong Medical Equipment industry.
The company's shares are up 7.0% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Beijing Chunlizhengda Medical Instruments you should be aware of, and 1 of them can't be ignored.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.